A practical reference on incretin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
== Health risks == Acrolein is toxic and is a strong irritant for the skin, eyes, and nasal passages. The main metabolic pathway for acrolein is the alkylation of glutathione. The WHO suggests a "tolerable oral acrolein intake" of 7.5 μg per day per kg of body weight. Although acrolein occurs in French fries (and other fried foods), the levels are only a few μg per kg, meaning that one would have to consume more than their body weight in fries every day to surpass the limit set by the WHO. In response to occupational exposures to acrolein, the US Occupational Safety and Health Administration has set a permissible exposure limit at 0.1 ppm (0.25 mg/m3) at an eight-hour time-weighted average. Acrolein acts in an immunosuppressive manner and may promote regulatory cells, thereby preventing the generation of allergies on the one hand, but also increasing the risk of cancer. Acrolein was identified as one of the chemicals involved in the 2019 Kim Kim River toxic pollution incident.
Scans conducted during the studies showed that Sharrock's brain exhibited a heightened connection between the conscious and sub-conscious parts of her brain, which may aid easier memory recall – in particular for events that took place earlier in life. In December 2017, a man named Joey DeGrandis was verified as having HSAM by James McGaugh and subsequently featured in an article in Time magazine. DeGrandis also reports having poor short-term memory, indicating that HSAM does not necessarily improve one's short-term memory abilities. A 63-year-old man, anonymised as "The Amazing Memory Man" (MM) was featured in a paper by Neuropsychology in March 2018, where it is reported that he "appreciates that his memory for personally experienced life events and general knowledge are both exceptional, whereas his imaging the future is only average" (after scoring 123 on Episodic, 123 on Semantic, 112 on Spatial, and 91 on Future remembering memory types, all with a mean of 100). In October 2018, it was reported that teenager Tyler Hickenbottom, who is an identical twin, had the condition, which allowed him to "remember every day of his life like it was yesterday". Tim Rogers, an American video game developer and journalist, claims to experience the condition in several of his published works. John Romero, a video game developer and co-founder of id Software, has often said he has hyperthymesia, including in his 2023 autobiography, Doom Guy: Life in First Person. In 2024, Emily Nash, an 18-year-old high school student with HSAM, was featured in a CTV W5 story.
==== 1300–1399 ==== Concession Statements (Prescribed Information) Regulations 1993 (S.I. 1993/1300) Gipsy Encampments (City of Hereford) Order 1993 (S.I. 1993/1301) South Wales Police (Amalgamation) (Amendment) (No. 2) Order 1993 (S.I. 1993/1302) Dyfed-Powys Police (Amalgamation) (Amendment) (No. 2) Order 1993 (S.I. 1993/1303) Seed Potatoes (Fees) (Scotland) Regulations 1993 (S.I. 1993/1311) Eastwood and East Kilbride Districts (Busby) Boundaries Amendment Order 1993 (S.I. 1993/1312) Margate Pier and Harbour Revision Order 1992 (SI 1993/1313) Integrated Administration and Control System Regulations 1993 (S.I. 1993/1317) Lewisham and Southwark (London Borough Boundaries) Order 1993 (S.I. 1993/1318) Greater London and Surrey (County and London Borough Boundaries) (No.3) Order 1993 (S.I. 1993/1319) Plant Health (Great Britain) Order 1993 (S.I. 1993/1320) Health and Safety (Fees) Regulations 1993 (S.I. 1993/1321) A500 Newcastle-Under-Lyme to Nantwich Trunk Road (Basford-Hough-Shavington Bypass and Slip Road) Order 1993 (S.I. 1993/1322) A500 Newcastle-Under-Lyme to Nantwich Trunk Road (Basford-Hough-Shavington Bypass) (Detrunking) Order 1993 (S.I. 1993/1323) Post Office (Abolition of Import Restrictions) Regulations 1993 (S.I. 1993/1324) Fishing Vessels (Safety Improvements) (Grants) Scheme 1993 (S.I. 1993/1325) Insurance Companies (Cancellation) Regulations 1993 (S.I. 1993/1327) Diseases of Animals (Therapeutic Substances) (Revocation) Order 1993 (S.I. 1993/1331) Foot-and-Mouth Disease (Sera and Glandular Products) (Revocation) Order 1993 (S.I.
Amanita virosa is a species of fungus in the class Agaricomycetes. In the UK, it has the recommended English name of destroying angel and is known internationally as the European destroying angel. Basidiocarps (fruit bodies) are agaricoid (mushroom-shaped) and pure white with a ring on the stipe and a sack-like volva at the base. The species occurs in Europe and northern Asia. It was formerly reported from North America, but similar-looking American species like A. bisporigera and A. ocreata are distinct. As the name suggests, the destroying angel is poisonous.
Sources: en.wikipedia.org
Northern: The northern section runs from the Canadian province of Newfoundland and Labrador to the Hudson River. It includes the Long Range Mountains and Annieopsquotch Mountains on the island of Newfoundland, the French Territorial Collectivity of Saint-Pierre and Miquelon southwest of Newfoundland, Chic-Choc Mountains and Notre Dame Range in Quebec and New Brunswick, scattered elevations and small ranges elsewhere in Nova Scotia and New Brunswick, the Longfellow Mountains in Maine, the White Mountains in New Hampshire, the Green Mountains in Vermont, and The Berkshires in Massachusetts, and Connecticut, the Metacomet Ridge Mountains in Connecticut and south-central Massachusetts, and the Adirondack Mountains in New York are all part of the Appalachian Mountains as defined by the governments of Canada and the United States.Mountains of the Long Range in Newfoundland, such as the Cabox and Gros Morne, reach heights of nearly 2,700 ft (800 m). In the Chic-Choc and Notre Dame Mountain ranges in Quebec, the higher summits rise above 4,000 ft (1,200 m) in elevation. Isolated peaks and small ranges in Nova Scotia and New Brunswick vary from 1,000 to 2,700 ft (300 to 800 m). In Maine, several peaks exceed 4,000 ft (1,200 m), including Mount Katahdin at 5,267 feet (1,605 m).
=== Warm temperature plants === These plants prefer to grow at temperatures of 18 °C (65 °F) to 30 °C (86 °F) Others – Begonia, Ylang Ylang – Cananga odorata, Cooktown Orchid – Dendrobium bigibbum, Tasmanian Blue Gum – Eucalyptus globulus, Poinsettia – Euphorbia pulcherima, Gladiolus – Gladiolus, Gumamela – Hibiscus rosa-sinensis, Busy Lizzie – Impatiens, Lobelia – Lobelia cardinalis, Oleander – Nerium oleander, Frangipani – Plumeria rubra, Petunia, Sampaguita – Jasminum sambac, Sturt's Desert Rose – Gossypium sturtianum, Waratah – Telopia specisissima, Royal Bluebell – Wahlenbergia gloriosa
To gain regulatory approval, the milbemycin oxime/lufenuron heartworm treatment was divested to Virbac. In March 2015, the company announced it would join Hanmi Pharmaceutical in developing and commercializing Hanmi's phase I Bruton's tyrosine kinase inhibitor HM71224 in a deal that could yield $690 million. A day later, however, the company announced another deal with China's Innovent Biologics to co-develop and commercialize at least three of Innovent's treatments over the next decade, in a deal which could generate up to $456 million; the collaboration was subsequently expanded in 2022, according to Innovent. As part of the deal, the company contributed its c-Met monoclonal antibody, and Innovent contributed a monoclonal antibody, which targets CD-20. The second compound from Innovent is a preclinical immunooncology molecule. The following week, the company announced it would restart its collaboration with Pfizer surrounding the Phase III trial of Tanezumab. Pfizer is expected to receive an upfront sum of $200 million from the company. In April 2015, Lilly engaged CBRE Group to sell its biomanufacturing facility in Vacaville, California, a 52 acres (0.21 km2) campus and facility that is one of the largest biopharmaceutical manufacturing centers in the US. In July 2016, Lechleiter retired and was succeeded by David Ricks. In January 2017, Elanco, at the time a subsidiary of Lilly, acquired Boehringer Ingelheim Vetmedica, a subsidiary of Boehringer Ingelheim's US feline, canine, and rabies vaccines portfolio, for $885 million.
The chemical structure of penicillin was first suggested by Abraham in 1942. Dorothy Hodgkin determined the correct chemical structure of penicillin using X-ray crystallography at Oxford in 1945. In 1945, the US Committee on Medical Research and the British Medical Research Council jointly published in Science chemical analyses conducted at different universities, pharmaceutical companies and government research departments. The report announced the existence of different forms of penicillin compounds which all shared the same structural component called β-lactam. The penicillins were designated by Roman numerals in UK (penicillin I, II, III and IV) in order of their discoveries, and known by letters (F, G, X, and K) referring to their origins or sources in the US, as below:
Additional design elements are common among contemporary In-N-Out locations. Matching In-N-Out's California-inspired palm tree theme, palm trees are sometimes planted to form an "X" in front of the restaurants. This is an allusion to founder Harry Snyder's favorite movie, Stanley Kramer's It's a Mad, Mad, Mad, Mad World, in which the characters look for a hidden treasure and find it under "the big W" made by four palm trees, with the middle two forming an "X".
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.